Zealand Pharma starts Phase 3 ZUPREME trials of petrelintide for chronic weight management

Bitget2026/09/22 15:00

Bitget offers one-stop trading for cryptocurrencies, stocks, and gold. Trade now!

A welcome pack worth 6200 USDT for new users! Sign up now!

Zealand Pharma launched the registrational Phase 3 ZUPREME program for once-weekly petrelintide in chronic weight management.
Results have not been presented; the program is intended to generate evidence for future regulatory filings and marketing applications.
Phase 3a comprises three placebo-controlled trials across obesity or overweight populations, including type 2 diabetes or established cardiovascular disease.
Enrollment is expected to total about 7,000 participants, positioning petrelintide for a potential large-scale commercial opportunity.
The decision follows earlier Phase 2 data indicating meaningful weight loss with tolerability broadly comparable to placebo.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Zealand Pharma A/S published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202609221100PRIMZONEFULLFEED1001274046) on September 22, 2026, and is solely responsible for the information contained therein.

Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.

Understand the market, then trade.

Bitget offers one-stop trading for cryptocurrencies, stocks, and gold.

Trade now！

Zealand Pharma starts Phase 3 ZUPREME trials of petrelintide for chronic weight management

You may also like

Crypto prices